Improving health is one of the toughest challenges facing the world today. As a global, innovation-driven biopharmaceutical company, AstraZeneca has a key contribution to make through the discovery, development, manufacturing and commercialisation of medicines for six important areas of healthcare: cancer, cardiovascular, gastrointestinal, infection, neuroscience and respiratory and inflammation.
AstraZeneca Egypt is engaged in the manufacture and supply of medicines that aim to make a real difference to the lives of Egyptians. Our business is driven by our mission to bring new innovative medicines into peoples’ lives. We are committed to working collaboratively, creatively, and with courage to achieve our goal of better health for patients:
- For patient and the healthcare community, we provide medicines for some of the world’s most serious illnesses, and we aim to provide assistance to enhance medical practice.
- For our employees, we provide a culture in which they feel appreciated, energised and rewarded for their contribution.
- For our stakeholders, we aim to deliver value through our continued focus on innovation and by running our business efficiently.
- For the wider community, we strive to be valued for the contribution our medicines make to society and trusted for the way in which we do business.
AstraZeneca has a solid presence in the Egyptian pharmaceutical market since 1968, when Astra opened its first office, followed by Zeneca Scientific in 1972. Today, AstraZeneca Egypt has around 400 employees, including the commercial operations and the manufacturing facility.
The AstraZeneca Egypt manufacturing facility is located in Sixth of October City. Inaugurated in 2006, the factory has the capacity to produce 400 million tablets and is currently operating 3 packing lines.
|Product||Generic name||Therapy area|
|Emla cream||lidocaine+prilocaine||Local anesthetic|
|Logimax||felodipine - ramipril||Gastrointestinal|
|Symbicort||budesonide - formoterol||Respiratory|
|Tenoret||atetonol – chlorothalidone||Cardiovascular|
|Tenoretic||atenolol - chlorothalidone||Cardiovascular|
|Zestoretic||lisinopril – hydrochlorothiazide||Cardiovascular|
Adverse event reporting
In order to monitor the safety of AstraZeneca products, we encourage reporting any side effects experienced while taking an AstraZeneca product to Dr. Dina Ahmed, Medical Affairs Manager at the following numbers:
Phone: +20 2 2702 5159
Fax: +20 2 2702 6880
Interested in joining us?
Please send your application to the following e-mail address: Career.Egypt@astrazeneca.com